Osteosarcoma is a rare and aggressive form of bone cancer primarily affecting children and young adults with a prevalence of approximately 3.4 cases per million annually. It is often treated with a combination of surgery and chemotherapy, with first-line treatments including agents such as methotrexate, cisplatin, and doxorubicin. Despite these therapies, the disease presents a high unmet clinical need due to limited effectiveness in advanced stages and recurrences. The growing focus on targeted therapies, immunotherapy, and personalized medicine is likely to drive significant progress in the osteosarcoma drug pipeline in the coming years.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to osteosarcoma.
Osteosarcoma treatment involves surgery to remove the tumor, often combined with chemotherapy. First-line chemotherapy includes methotrexate, cisplatin, and doxorubicin. For recurrent or metastatic cases, targeted therapies and immunotherapy are being explored. Despite these options, the high risk of relapse highlights the need for more effective, personalized treatment strategies.
This product will be delivered within 3-5 business days.
Report Coverage
The Osteosarcoma Drug Pipeline Insight Report by the publisher gives comprehensive insights into osteosarcoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for osteosarcoma. The osteosarcoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The osteosarcoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with osteosarcoma treatment guidelines to ensure optimal care practices.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to osteosarcoma.
Osteosarcoma Pipeline Outlook
Osteosarcoma is a malignant bone tumor that primarily affects adolescents and young adults, often occurring in long bones like the femur or tibia. It typically develops when abnormal cells grow uncontrollably, leading to aggressive bone destruction. With an incidence of about 3.4 cases per million people annually, the drug pipeline for osteosarcoma focuses on advanced treatments to improve survival rates and quality of life.Osteosarcoma treatment involves surgery to remove the tumor, often combined with chemotherapy. First-line chemotherapy includes methotrexate, cisplatin, and doxorubicin. For recurrent or metastatic cases, targeted therapies and immunotherapy are being explored. Despite these options, the high risk of relapse highlights the need for more effective, personalized treatment strategies.
Osteosarcoma Epidemiology
Osteosarcoma has an incidence of approximately 3.4 cases per million people annually, with a notable impact on younger populations. In the United States, there are around 440 cases yearly among individuals aged 0 to 19 years, estimating approximately 82 million in this age group. This rare but aggressive cancer highlights a critical unmet need, spurring advancements in targeted therapies and immunotherapies to improve treatment outcomes.Osteosarcoma Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of osteosarcoma drug candidates based on several segmentations, including:By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
- Small Molecules
- Monoclonal Antibodies
- Immunotherapies
- Gene Therapies
- Targeted Therapies
By Route of Administration
- Oral
- Parenteral
- Others
Osteosarcoma Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total osteosarcoma clinical trials.Osteosarcoma - Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the osteosarcoma pipeline analysis include small molecules, monoclonal antibodies, immunotherapies, gene therapies, and targeted therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for osteosarcoma.Osteosarcoma Clinical Trials Therapeutic Assessment - Competitive Dynamics
The osteosarcoma drug report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in osteosarcoma clinical trials:- MedPacto, Inc.
- Beijing Immunochina Medical Science & Technology Co., Ltd.
- Hansoh BioMedical R&D Company
- Ipsen
- Base Therapeutics (Shanghai) Co., Ltd.
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Cellectar Biosciences, Inc.
- AstraZeneca
- Umoja BioPharma, Inc.
- K-Group, Beta, Inc.
- BTG International Inc.
- Bristol-Myers Squibb
- Genentech, Inc.
Osteosarcoma Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for osteosarcoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of osteosarcoma drug candidates.Drug: Cabozantinib
The Phase II study, sponsored by Ipsen, aims to assess the efficacy, safety, and pharmacokinetics of maintenance cabozantinib plus best supportive care (BSC) versus BSC alone in children, adolescents, and young adults with unresectable residual osteosarcoma. The study is expected to be completed by June 2028, with an estimated 90 participants enrolled.Drug: Vactosertib
MedPacto, Inc., is sponsoring a study that aims to assess the safety, tolerability, and antitumor activity of Vactosertib in adolescents and adults with recurrent, refractory, or progressive osteosarcoma. The Phase I/II study will evaluate the drug's efficacy and pharmacokinetics. The study, with around 48 participants enrolled, is expected to be completed by November 2025. The primary objective of the clinical trial is to determine the maximum tolerated dose and overall response rate.Drug: 1200mg of TQB2928 Injection + Anlotinib
The drug TQB2928 injection, combined with Anlotinib hydrochloride capsules, is sponsored by Chia Tai Tianqing Pharmaceutical Group and Nanjing Shunxin Pharmaceutical Co., Ltd. The objective of this Phase 1 study is to evaluate the efficacy and safety of the combination in patients with relapsed or metastatic osteosarcoma and other solid tumors. The study, enrolling about 43 participants, is expected to be completed by February 2026.Reasons To Buy This Report
The Osteosarcoma Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for osteosarcoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into osteosarcoma collaborations, regulatory environments, and potential growth opportunities.Key Questions Answered in the Osteosarcoma - Pipeline Insight Report
- What is the current landscape of osteosarcoma pipeline drugs?
- Which companies/institutions are developing osteosarcoma emerging drugs?
- How many phase II drugs are currently present in osteosarcoma pipeline drugs?
- Which company is leading the osteosarcoma pipeline development activities?
- What is the current osteosarcoma therapeutic assessment?
- What are the opportunities and challenges present in the osteosarcoma drug pipeline landscape?
- What is the efficacy and safety profile of osteosarcoma pipeline drugs?
- Which companies/institutions are involved in osteosarcoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in osteosarcoma?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Osteosarcoma
4 Patient Profile: Osteosarcoma
5 Osteosarcoma: Epidemiology Snapshot
6 Osteosarcoma: Market Dynamics
7 Osteosarcoma: Key Facts Covered
8 Osteosarcoma, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Osteosarcoma Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Osteosarcoma Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Osteosarcoma Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Osteosarcoma Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Osteosarcoma, Key Drug Pipeline Companies
